Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals filed an 8-K reporting new preclinical results for Telomir-1. In human keratinocyte (HaCaT) cells, Telomir-1 produced a strong, dose- and time-dependent reduction of intracellular ferrous iron (Fe²⁺), with greater effect than the FDA‑approved iron chelator Deferoxamine (DFO) under equivalent conditions.
The study used FerroOrange live-cell imaging and observed lower Fe²⁺ signal at three, six, and sixteen hours, indicating cell penetration and iron‑modulating activity at low concentrations. The company also noted a zinc‑formulated version, Telomir‑Zn, designed to exchange metal ions by binding excess reactive metals such as iron and copper while contributing zinc, a cofactor for enzymes tied to antioxidant defense and DNA stability. The findings support ongoing research into metal‑ion balance, oxidative stress, and epigenetic regulation in aging and degenerative disease.
Telomir Pharmaceuticals (NASDAQ: TELO) filed its Q3 2025 10‑Q, reporting ongoing preclinical development and continued losses. Net loss was $1.1 million for the quarter and $8.4 million year‑to‑date, with no revenue. Operating costs in Q3 were $1.15 million, driven by $0.76 million in R&D and $0.39 million in G&A.
Cash rose to $7.33 million as of September 30, 2025, supported by financings: $5.55 million in ATM proceeds during the nine months and a $3.0 million related‑party equity investment at a premium. Subsequent to quarter end, the company raised an additional $1.00 million via ATM block sales. The company disclosed substantial doubt about its ability to continue as a going concern despite indicating current cash is expected to fund operations through the third quarter of 2026.
Shares outstanding were 33,830,971 at September 30, 2025 and 34,380,971 as of November 7, 2025. Telomir executed a binding LOI on October 17, 2025 to acquire TELI Pharmaceuticals, aiming to consolidate worldwide rights to Telomir‑1, with up to $5 million in potential shareholder contributions tied to milestones, subject to approvals.
Telomir Pharmaceuticals (TELO) announced new preclinical data on Telomir-1 in a mouse model of aggressive prostate cancer, focusing on DNA methylation changes in two defense genes, CASP8 (apoptosis) and GSTP1 (glutathione-based detoxification).
On Day 21, Telomir-1 was associated with reduced DNA methylation of both CASP8 and GSTP1 versus vehicle and chemotherapy, suggesting potential re-activation of apoptosis and detoxification-related gene functions. The combination of Telomir-1 and chemotherapy showed lower methylation than chemotherapy alone in this model. Rapamycin showed an initial reduction at Day 10 that partially rebounded by Day 21, while Telomir-1 continued a progressive, more sustained decrease. The company believes DNA-methylation control may be an important area of ongoing evaluation for Telomir-1 in oncology research.
Telomir Pharmaceuticals (NASDAQ: TELO) signed a binding LOI to acquire TELI Pharmaceuticals in a stock-for-stock deal, consolidating worldwide intellectual property and development rights to its lead candidate, Telomir-1.
The agreement includes up to $5 million in cash contributions from certain TELI shareholders: $1 million at closing, $2 million upon FDA acceptance of an IND, and $2 million upon initiation of a Phase 1/2 study. Shares tied to the $4 million in milestone contributions will be allocated at closing and issued upon receipt of each payment. Closing is not contingent on receiving the milestone funds.
The LOI imposes a six-month lockup on shares issued to TELI holders and is subject to due diligence, board and stockholder approvals, regulatory clearances, and definitive agreements. If completed, Telomir would hold unified global rights to Telomir-1, aiming to simplify development and partnering.
Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.
The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.
Telomir Pharmaceuticals, Inc. reported new preclinical findings showing that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies. As Telomir-1 concentrations increased in human TNBC cell models, cancer cell survival dropped in a clear, concentration-dependent manner, and adding iron back restored cell growth, indicating the effect is tied to iron-dependent energy regulation.
The company explains that TNBC cells are highly metabolically active and rely heavily on iron, and that Telomir-1 appears to exploit this vulnerability while normal cells manage iron differently. Telomir-1 has also been shown previously to reset abnormal DNA methylation patterns, and the new data suggest its impact on TNBC may involve iron-dependent epigenetic enzymes linked to aggressive behavior and treatment resistance. Telomir plans to expand these studies to other cancer types and perform additional animal studies as it prepares an Investigational New Drug submission.
Telomir Pharmaceuticals, Inc. reported new preclinical findings for its lead investigational compound, Telomir-1, in aggressive prostate cancer models. The studies showed that Telomir-1 can reset abnormal DNA methylation and restore the function of two key tumor suppressor genes, MASPIN and RASSF1A, which are often silenced in cancer and are closely linked to metastasis and treatment resistance.
In an in vivo aggressive prostate cancer model, MASPIN was silenced by DNA hypermethylation, and Telomir-1 reversed chemotherapy-induced DNA methylation to restore MASPIN activity. Telomir-1 also reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. The company states that reactivating these genes may help restore natural tumor defenses, counteract chemotherapy-induced resistance, and limit cancer metastasis as part of its ongoing preclinical and IND-enabling development of Telomir-1.
John Paul DeJoria, both personally and as trustee of the John Paul DeJoria Family Trust, reports beneficial ownership of 1,774,900 shares of Telomir Pharmaceuticals, Inc. common stock, representing 5.50% of the outstanding class. The filing indicates Mr. DeJoria has sole voting and dispositive power over these shares and states the shares were not acquired to change or influence control of the company. The filing lists the issuer's principal office in Miami, FL, and provides a business address for the reporting person in Georgetown, TX. A power of attorney is attached as an exhibit.
Telomir Pharmaceuticals reported new in vitro pharmacology data for its lead candidate Telomir-1, showing that the drug potently inhibits three members of the KDM5 histone demethylase family. These enzymes help cancers and aging cells silence protective genes and activate harmful inflammatory pathways.
The company notes that Telomir-1 had already demonstrated activity against other histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A), while sparing broad acetyltransferases linked to systemic toxicity. In earlier in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressor genes such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.
Taken together, Telomir-1 is described as having broad-spectrum activity across DNA methylation and multiple histone demethylation pathways, supporting ongoing IND-enabling studies, GMP scale-up, and additional preclinical work in aggressive cancers and aging models.
Telomir Pharmaceuticals reported new preclinical results in aggressive human prostate cancer cell models showing that its investigational therapy Telomir-1 reverses DNA methylation–driven silencing of CDKN2A, a key tumor suppressor often described as the body’s natural “cell cycle brake.” In these PC3 xenograft models, Telomir-1 inhibited DNA hypermethylation of CDKN2A and outperformed both Rapamycin and chemotherapy on this measure.
The company notes that earlier data showed Telomir-1 also resets DNA methylation of STAT1, a master immune regulator. Together, the STAT1 and CDKN2A findings suggest Telomir-1 can reset epigenetic silencing across multiple tumor suppressor and immune pathways. Telomir is evaluating Telomir-1 in several aggressive cancer types and continues its pre-IND work, including CMC scale-up toward GMP production and IND-enabling studies ahead of a planned first IND submission.
FAQ
What is the current stock price of Telomir Pharms (TELO)?
What is the market cap of Telomir Pharms (TELO)?
